RESEARCH ARTICLE


Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis



Derek J Quinn, Sinéad Weldon, Clifford C Taggart*
Centre for Infection and Immunity, Whitla Medical Building, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland


Article Metrics

CrossRef Citations:
3
Total Statistics:

Full-Text HTML Views: 3960
Abstract HTML Views: 1637
PDF Downloads: 758
Total Views/Downloads: 6355
Unique Statistics:

Full-Text HTML Views: 1644
Abstract HTML Views: 909
PDF Downloads: 509
Total Views/Downloads: 3062



Creative Commons License
© Quinn et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Centre for Infection and Immunity, Whitla Medical Building, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland; Tel: 00442890972714; Fax: 00442890632697; E-mail: c.taggart@qub.ac.uk


Abstract

Cystic Fibrosis (CF) is the most common fatal inherited disease of Caucasians, affecting about 1 in 3000 births. Patients with CF have a recessive mutation in the gene encoding the CF transmembrane conductance regulator (CFTR). CFTR is expressed in the epithelium of many organs throughout the exocrine system, however, inflammation and damage of the airways as a result of persistent progressive endobronchial infection is a central feature of CF. The inflammatory response to infection brings about a sustained recruitment of neutrophils to the site of infection. These neutrophils release various pro-inflammatory compounds including proteases, which when expressed at aberrant levels can overcome the endogenous antiprotease defence mechanisms of the lung. Unregulated, these proteases can exacerbate inflammation and result in the degradation of structural proteins and tissue damage leading to bronchiectasis and loss of respiratory function. Other host-derived and bacterial proteases may also contribute to the inflammation and lung destruction observed in the CF lung. Antiprotease strategies to dampen the excessive inflammatory response and concomitant damage to the airways remains an attractive therapeutic option for CF patients.

Keywords: Neutrophil, macrophage, bacteria, proteases, protease inhibitors..